Intra-Cellular Therapies, Inc.
ITCI
Rank in Stocks
#1690
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Share Price
$131.87
Last synced: 2025-04-02
Market Cap
$12.68B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Intra-Cellular Therapies, Inc. (ITCI)
Category
Healthcare
Revenue for Intra-Cellular Therapies, Inc. (ITCI)
Revenue in Dec 2024 TTM: $680.64M
According to Intra-Cellular Therapies, Inc. latest financial reports the company's current revenue (TTM) is $680.64M. In 2023 the company made a revenue of $464.37M an increase over the revenue in the year 2022 that was $249.13M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Intra-Cellular Therapies, Inc. from 2013 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $680.64M | -0.03% |
| 2024 | $680.85M | 46.62% |
| 2023 | $464.37M | 86.40% |
| 2022 | $249.13M | 204.91% |
| 2021 | $81.71M | 262.65% |
| 2020 | $22.53M | 37,071.49% |
| 2019 | $60.61K | 0.00% |
| 2018 | 0.00 | -100.00% |
| 2017 | $245.84K | -25.66% |
| 2016 | $330.70K | 261.96% |
| 2015 | $91.36K | -84.17% |
| 2014 | $577.30K | -78.91% |
| 2013 | $2.74M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 871.39% |
IN
|
